Home > Result Summaries: Compounds > naratriptan > Result Summary for EPI40050_1

Result Summary for EPI40050_1

Result Summary

Protocol ID:	EPI40050_1
Clinical Study ID:	EPI40050
Official Title:	The Sumatriptan and Naratriptan Pregnancy Registry
Phase:	Phase 4
Study Indications or Diseases:	Migraine Disorders
Generic Name:	naratriptan
Trade/Product Name:	amerge;naramig
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Eldridge RR, Ephross SA. Monitoring birth outcomes in the sumatriptan pregnancy registry. Prim Care Update Ob Gyns. 1998; 5(4): 190. Sumatriptan and Naratriptan Pregnancy Registry. Interim Report 1 January 1996 through 31 October 2006. Issued February 2007. Available at: http://pregnancyregistry.gsk.com/index.html Eldridge RR, Ephross SA, Heffner CR, Tennis PS, Stender DM, White AD. Monitoring pregnancy outcomes following prenatal drug exposure through prospective pregnancy registries and passive surveillance: a pharmaceutical company commitment. Prim Care Update Ob Gyns. 1998; 5(4): 190-191. Reiff-Eldridge RR, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynaecol. 2000; 182 (1 Pt 1): 159-63.